Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab plus chemotherapy for squamous NSCLC with brain metastases
NCT05207904Phase 2Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Jun 2021
- Primary completion
- Dec 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in squamous cell carcinoma of the lung (SCCL), sponsored by Sun Yat-sen University. Status: unknown.
02
Drugs
tislelizumab
03
Conditions
squamous cell carcinoma of the lung (SCCL)
Beyond the preview
Go deeper on NCT05207904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05207904.